Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months

Autor: Manuel Pérez-Encinas, Pilar Giraldo, L.F. Casado, Carmen Calle, María-Jesús Peñarrubia, Joaquin Martinez-Lopez, J.L. Steegmann, José-Valentín García-Gutiérrez, Luis Palomera, Isabel Massague, Carmen Burgaleta, Guiomar Bautista, Raquel de Paz, Jose Angel Hernandez-Rivas, Begoña Maestro, Santiago Osorio, María-José Requena, Nuria García-Ormeña

Publikováno v: Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Cancer Medicine

Chronic myeloid leukemia patients display heterogeneous responses to imatinib. Survival depends on baseline clinical characteristics (including prognostic scoring systems) and on early response (such as >10% BCR-ABL/ABL ratio at 3 months of therapy).

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cbfc8d24502055423622ab87243ef2d4
https://doi.org/10.1002/cam4.440

Real Life Long-Term Survival Analysis in Patients with Chronic Myeloid Leukemia Treated with Tkis in Spain

Autor: Pilar Giraldo, Manuel Pérez-Encinas, Raquel de Paz, Jose Angel Hernandez-Rivas, Maria José Requena, Nuria García-Ormeña, Juan Luis Steegmann, Santiago Osorio, María Jesús Peñarrubia, Luis Felipe Casado Montero, Carmen Calle, Guiomar Bautista, Luis Palomera, Valentín García Gutiérrez, Joaquin Martinez-Lopez

Publikováno v: Blood. 128:3074-3074

Introduction: TKIs introduction in the treatment of chronic myeloid leukemia (CML) has offered an outstanding improvement in prognosis, especially in survival. Data about TKIs were obtained from clinical trials but little is known about their transla

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::84efc2c7aabd1bfbe6082899d962c85a
https://doi.org/10.1182/blood.v128.22.3074.3074